BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study.
Authors: Jean Y. Ko, Van T. Tong, Jennifer M. Bombard, Donald K. Hayes, John Davy, et al
Drug and Alcohol Dependence, June 2018
—
BACKGROUND: We sought to describe the correlates of marijuana use during and after pregnancy, and to examine the independent relationship between prenatal marijuana use and infant outcomes. STUDY DESIGN: We used state-specific data from the Pregnancy Risk Assessment Monitoring…
Dangerous plants in dermatology: Legal and controlled.
Authors: Deeptej Singh, Juliya Fisher, Devorah Shagalov, Aakaash Varma, Daniel M. Siegel
Clinics in Dermatology, May-June 2018
—
The plant and mushroom kingdoms have species used for intoxication, inebriation, or recreation. Some of these species are toxic. Given that many of these plants or substances are illegal and have histories of abuse, much of the research regarding therapeutic application is bas…
Transfer of Inhaled Cannabis Into Human Breast Milk.
Authors: Teresa Baker, Palika Datta, Kathleen Rewers-Felkins, Heather Thompson, Raja Kallem, Thomas Hale
Obstetrics & Gynecology, May 2018
—
OBJECTIVE: To evaluate the transfer of delta-9-tetrahydrocannabinol and its metabolites into human breast milk after maternal inhalation of 0.1 g cannabis containing 23.18% delta-9-tetrahydrocannabinol. METHODS:
In this pilot pharmacokinetic study, breast milk samples were col…
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Authors: Elisabeth G. Celius, Carlos Vila
Brain and Behavior, 6 April 2018
—
BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associate…
Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.
Authors: Marie Stefanie Kejser Starzer, Merete Nordentoft, Carsten Hjorthøj
American Journal of Psychiatry, April 2018
—
OBJECTIVE: The authors investigated the rates of conversion to schizophrenia and bipolar disorder after a substance-induced psychosis, as well as risk factors for conversion. METHOD: All patient information was extracted from the Danish Civil Registration System and the Psychi…
Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis.
Authors: Antti Mustonen, Solja Niemelä, Tanja Nordström, Graham K. Murray, Pirjo Mäki, et al
The British Journal of Psychiatry, April 2018
—
BACKGROUND: The association between cannabis use and the risk of psychosis has been studied extensively but the temporal order still remains controversial. Aims To examine the association between cannabis use in adolescence and the risk of psychosis after adjustment for prodro…
Plasma anandamide concentrations are lower in children with autism spectrum disorder.
Authors: Debra S. Karhson, Karolina M. Krasinska, Jamie Ahloy Dallaire, et al
Molecular Autism, 12 March 2018
—
BACKGROUND: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by restricted, stereotyped behaviors and impairments in social communication. Although the underlying biological mechanisms of ASD remain poorly understood, recent preclinical research ha…
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018
—
Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…
A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes.
Authors: Lynda G. Balneaves, Abeer Alraja, Daniel Ziemianski, Fairleth McCuaig, Mark Ware
Cannabis and Cannabinoid Research, March 2018
—
Introduction: In Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR) has given nurse practitioners (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This expansion in NPs’ scope of practice underscores the importance…
Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Authors: Juan A. Paez, Nuria E. Campillo
Current Medicinal Chemistry, 25 February 2018
—
The discovery of cannabinoid receptors at the beginning of the 1990s, CB1 being cloned in 1990 and CB2 cloned in 1993, and the availability of selective and potent cannabimimetics could only be justified by the existence of endogenous ligands that are capable of binding to the…
Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: A Systematic Review.
Authors: Divya Ravi, Mehrnaz Ghasemiesfe, Deborah Korenstein, Thomas Cascino, Salomeh Keyhani
Annals of Internal Medicine, 6 February 2018
—
BACKGROUND: Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. PURPOSE: To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. DATA SOURCES: PubMed, MEDLINE, EMBASE, Psy…
Cannabis in Parkinson’s Disease: Hype or help?
Authors: Tina Mainka, Jan Stork, Ute Hidding, Carsten Buhmann
Fortschritte der Neurologie · Psychiatrie, February 2018
—
Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms…